i2o Therapeutics: i2O Therapeutics Announces Research Collaboration and Option Agreement with Janssen to Investigate the Oral Delivery of Macromolecules

i2O Therapeutics, a developer of oral biologic products based on its proprietary ionic liquid platform, today announced a collaboration and option agreement with Janssen Biotech, Inc., for Janssen Research & Development to evaluate the use of ionic liquid technology for the oral delivery of macromolecules.